ORAL MEDICATION

Achondroplasia · Hypochondroplasia · Infigratinib · PROPEL · QED Therapeutics

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

SOURCE: BRIDGEBIO.COM/NEWS – BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan – BridgeBio to receive upfront payment of USD 100 million with…

Read More BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
Tyra Biosciences · TYRA-300

Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Agent, Into Achondroplasia

In preclinical models, TYRA-300 demonstrated significant increases in growth and bone lengthPhase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024-Conference call and webcast today, March 1st, at 8:00…

Read More Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Agent, Into Achondroplasia

translate ?